Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More
Xconomy
NOVEMBER 11, 2016
Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. Patent and Trademark Office. Now, the U.S. CRISPR DEVELOPMENTS.
87 
Let's personalize your content